Whipple's disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature

J Med Case Rep. 2015 Jul 28:9:165. doi: 10.1186/s13256-015-0632-6.

Abstract

Introduction: Whipple's disease is a rare infectious disease caused by Tropheryma whipplei with protean clinical manifestations. This infection may mimic chronic inflammatory rheumatisms.

Case presentation: We report two cases of Whipple's disease diagnosed in the context of an inflammatory disease with anti-tumor necrosis factor alpha failure. The first patient was a 58-year-old white man with psoriatic spondylarthritis, who was treated with adalimumab, etanercept, infliximab, tocilizumab and golimumab. The second was a 73-year-old white man with rheumatoid arthritis, who received treatment with infliximab, then etanercept and rituximab.

Conclusions: Whipple's disease should be suspected in all patients diagnosed with chronic inflammatory rheumatism, partially controlled or not controlled by treatment with tumor necrosis factor alpha blockers, whose condition worsens after treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adalimumab / therapeutic use
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Diagnosis, Differential
  • Etanercept / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Male
  • Middle Aged
  • Rheumatic Fever / complications*
  • Rheumatic Fever / drug therapy*
  • Rituximab / therapeutic use
  • Tumor Necrosis Factor-alpha / drug effects*
  • Whipple Disease / complications*
  • Whipple Disease / diagnosis*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • golimumab
  • Infliximab
  • Adalimumab
  • tocilizumab
  • Etanercept